


Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience

Journal Article

Author(s):

Kothari, Prachi; [Marass, Francesco](#) ; Yang, Julie L.; Stewart, Caitlin M.; Stephens, Dennis; Patel, Juber; Hasan, Maysun; Jing, Xiaohong; Meng, Fanli; [Enriquez, Jeanette](#); Huberman, Kety; Viale, Agnes; Francis, Jasmine H.; Berger, Michael F.; Shukla, Neerav; Abramson, David H.; Dunkel, Ira J.; Tsui, Dana W. Y.

Publication date:

2020-09

Permanent link:

<https://doi.org/https://doi.org/10.3929/ethz-b-000426915>

Rights / license:


[Creative Commons Attribution 4.0 International](#)

Originally published in:

Cancer Medicine 9(17), <https://doi.org/10.1002/cam4.3144>

ORIGINAL RESEARCH

Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience

Prachi Kothari¹  | Francesco Marass^{2,3}  | Julie L. Yang¹  | Caitlin M. Stewart¹  |
 Dennis Stephens¹ | Juber Patel¹ | Maysun Hasan¹ | Xiaohong Jing¹ | Fanli Meng¹ |
 Jeanette Enriquez¹ | Kety Huberman¹ | Agnes Viale¹ | Jasmine H. Francis^{1,4} |
 Michael F. Berger^{1,4} | Neerav Shukla¹ | David H. Abramson^{1,4} | Ira J. Dunkel^{1,4}  |
 Dana W. Y. Tsui^{1,4} 

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA

²ETH Zurich, Basel, Switzerland

³SIB Swiss Institute of Bioinformatics, Basel, Switzerland

⁴Weill Cornell Medical College, NY, USA

Correspondence

Dana W. Y. Tsui, Memorial Sloan Kettering Cancer Center, 417 E. 68th Street, New York, NY 10065, USA.

Email: tsuiw@mskcc.org

and

Ira J. Dunkel, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA

Email: dunkeli@mskcc.org

Funding information

We would like to acknowledge the generous support from the National Cancer Institute Cancer Center Support Grant (Grant No. P30 CA008748), the Whit Whit Fund, and the Kristen Ann Carr Fund (PK).

Abstract

Purpose: The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to tumor tissue for molecular profiling, especially in unilateral retinoblastoma, and hinders the confirmation of somatic *RB1* mutations necessary for genetic counseling. Plasma cell-free DNA (cfDNA) has provided a platform for noninvasive molecular profiling in cancer, but its applicability in low tumor burden retinoblastoma has not been shown. We analyzed cfDNA collected from 10 patients with available tumor tissue to determine whether sufficient tumor derived cfDNA is shed in plasma from retinoblastoma tumors to enable noninvasive *RB1* mutation detection.

Methods: Tumor tissue was collected from eye enucleations in 10 patients diagnosed with advanced intra-ocular unilateral retinoblastoma, three of which went on to develop metastatic disease. Tumor *RB1* mutation status was determined using an FDA-cleared tumor sequencing assay, MSK-IMPACT. Plasma samples were collected before eye enucleation and analyzed with a customized panel targeting all exons of *RB1*.

Results: Tumor-guided genotyping detected 10 of the 13 expected somatic *RB1* mutations in plasma cfDNA in 8 of 10 patients (average variant allele frequency 3.78%). Without referring to *RB1* status in the tumor, de novo mutation calling identified 7 of the 13 expected *RB1* mutations (in 6 of 10 patients) with high confidence.

Conclusion: Plasma cfDNA can detect somatic *RB1* mutations in patients with unilateral retinoblastoma. Since intraocular biopsies are avoided in these patients because of concern about spreading tumor, cfDNA can potentially offer a noninvasive

Ira J Dunkel and Dana W. Y. Tsui co-senior authors

This study was approved by the institutional ethics committee and informed consent was obtained from all participants.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Cancer Medicine* published by John Wiley & Sons Ltd.

platform to guide clinical decisions about treatment, follow-up schemes, and risk of metastasis.

KEYWORDS

liquid biopsy, molecular profiling in retinoblastoma, plasma cell-free DNA, *RBI* mutation, retinoblastoma

1 | INTRODUCTION

Retinoblastoma is the most common primary intraocular malignancy of childhood. Two thirds of all cases occur in children less than 2 years old with an age-adjusted annual incidence in children aged 0-4 of 10-14 cases per 1 million.¹ This corresponds to 1 case per 15,000-20,000 live births worldwide. About 70% of cases present with unilateral disease.²⁻⁴ The inciting factor leading to development of retinoblastoma is a loss of function mutation in the *RBI* gene on chromosome 13, the first described tumor suppressor.^{5,6} Biallelic mutations of the *RBI* tumor suppressor gene are seen in both heritable and non-heritable forms of retinoblastoma.^{2,7} In heritable retinoblastoma cases, the initial hit to the *RBI* gene occurs at the germline level and the second mutation occurs in a retinal cell at the somatic level leading to tumor formation. These patients typically present with bilateral disease or multifocal disease earlier in life. In non-heritable cases, patients develop unilateral tumors. In these cases, two random somatic hits must occur in the *RBI* gene of a single retinal cell to allow for the tumor to arise.⁷⁻⁹ A small subset of patients who develop unilateral retinoblastoma have been found to have *MYCN* amplification and no *RBI* alterations.^{9,10}

Identification and classification of the *RBI* mutation is important for clinical decision making in treatment of retinoblastoma and providing guidance to the patients and their families. Historically definitive standard of care treatment for unilateral retinoblastoma has been enucleation² leading to loss of vision and cosmetic changes; however improvements in treatment options, such as the introduction of ophthalmic artery chemosurgery, has significantly improved ocular survival in patients with unilateral and bilateral retinoblastoma.^{11,12} At Memorial Sloan Kettering Cancer Center, around 95% of patients with retinoblastoma are treated with intra-arterial chemotherapy or laser to preserve their vision.^{11,13} Furthermore, tumor biopsy at diagnosis is not recommended due to fear of tumor seeding and spread of disease.^{14,15} These factors have led to a reduction in tumor-based genetic profiling on a large proportion of patients. If tumor tissue is not obtained; a molecular diagnosis cannot be made to determine if the evolution of the patient's tumor derived from somatic mutations only and this hinders definitive clinical *RBI* genetic testing and counseling.

A small percentage of patients with unilateral disease (10%-15%) carry a germline *RBI* mutation.^{2,9,16} The diagnosis of heritable retinoblastoma can be made clinically in patients who present with bilateral disease or have a positive family history, but a clinical issue arises when a patient presents with unilateral disease, does not undergo enucleation, and a germline *RBI* mutation is not identified in normal blood. While this likely indicates that a germline mutation is not present, the test is formally considered non-informative since the tumor's *RBI* mutation is unknown and the absence cannot be confirmed in the blood. Therefore, these patients frequently undergo serial ophthalmology exams under anesthesia to assess for development of bilateral disease. The patients with heritable disease are also at higher risk for the development of secondary malignancies and will require additional screening tests as well as additional screening for their families.¹⁷⁻²⁰ With the ability to show that a somatic *RBI* mutation is driving the malignancy, the number of eye exams under anesthesia may be reduced. The patient and family can be reassured that the individual does not have an increased risk of other cancers versus the general population and, therefore, does not need increased cancer screening tests. In addition, the knowledge of a somatic *RBI* mutation can eliminate anxiety concerning the risk of retinoblastoma for current and future family members. Previous reports have shown that DNA from aqueous humor or cerebrospinal fluid in patients with retinoblastoma can reveal tumor-derived genetic information^{14,21,22}; however, obtaining these fluids are still invasive procedures. Hence, a blood-based noninvasive test for molecular profiling is needed.

Circulating plasma cell-free DNA (cfDNA) based assays have demonstrated promise as a noninvasive tool for molecular profiling across a broad spectrum of cancer types, aiding in diagnosis,²³ detecting minimal residual disease, monitoring responses, revealing resistance mechanisms, and tracking clonal evolution during therapy.^{24,25} In plasma, only a small fraction of cfDNA is tumor derived, depending on cancer type, disease stage^{26,27} and tumor volume.²⁸ This tumor-derived cfDNA is shed into circulation from tumor cells possibly via secretion, apoptosis, and necrosis.²³ It was unclear whether *RBI* mutations could be detected in cfDNA due to the low burden of disease when compared to other solid tumors. In this proof of concept study, we demonstrate the feasibility of detecting somatic *RBI* mutations in plasma cfDNA of patients with retinoblastoma (Figure 1). We focused on

treatment-naïve patients that were planned to receive primary enucleation, in order to minimize any confounding factors introduced by prior treatment.

2 | METHODS

2.1 | Patient recruitment and blood collection

This study involved ten patients with advanced intra-ocular unilateral retinoblastoma who were planned for primary enucleations (Table 1). Three patients from this cohort went on to develop metastatic disease. The table notes each patient's clinical status as of March 2020 as well as specific features of their advanced unilateral disease. This rate of metastasis is relatively higher than the general retinoblastoma population because over 95% of the retinoblastoma patients at MSKCC receive treatment that preserves the eyes, and those who require enucleation tend to have more advanced disease. P19 presented to this institution after receiving 1 cycle of chemotherapy at an outside institution as the parents did not initially consider enucleation for personal reasons. As all of these patients were undergoing eye enucleation, the tumor molecular profiles were used to guide identification of the *RB1* mutations in plasma cfDNA.

Parents or legal guardians of all the participants in this study provided consent for plasma collection and tumor profiling on an institutional review board approved protocol. A 10mL whole blood sample was collected from each patient in a Streck cfDNA blood collection tube (STRECK). Blood samples were centrifuged with a double centrifugation protocol (1600 g for 10 minutes followed by 14000 g for 10 minutes), and the plasma and buffy coat (portion of blood containing the white

blood cells) fractions were separated and stored. Genomic DNA was extracted from the buffy coat using the QIAGEN DNA extraction kit (QIAGEN). CfDNA was extracted from plasma using the QIAGEN QIASymphony platform (QIAGEN). Quality and quantity of cfDNA were evaluated with automated electrophoresis using Fragment Analyzer with High Sensitivity Genomic DNA Analysis Kit (Advanced Analytical).

2.2 | Genetic analysis of tumor by MSK-IMPACT

Tumor molecular profiling from enucleation specimens and patient matched normal blood samples were analyzed by MSK-IMPACT, an FDA-cleared clinical targeted sequencing assay that interrogates over 400 cancer-associated genes as previously described.^{29,30} This panel includes all coding exons in *RB1*. The somatic mutations in *RB1* were identified using a previously described bioinformatics pipeline^{29,30} and were manually reviewed using Integrated Genomics Viewer (IGV) software version 2.3.36.³¹

2.3 | Custom targeted sequencing of cfDNA

Plasma cfDNA was sequenced following hybridized capture using a targeted custom capture panel that includes all of the exons in the *RB1* gene. CfDNA libraries were prepared using the KAPA Hyper protocol (Kapa Biosystems). Custom DNA probes targeting the 27 exons of *RB1* and selected regions with heterozygous SNPs were combined in a single capture panel (Integrated DNA Technologies). Pre-capture libraries were quantified with Qubit (Invitrogen) and an equal mass of each DNA library (~200 ng per sample) was pooled for hybridization capture using a “double capture” protocol modified from the NimbleGen SeqCap Target Enrichment System (Roche). The first capture was incubated at 55°C for 16 hours, followed by post capture purification and 16 cycles of PCR amplification. After PCR clean-up, the captured target library was processed by a secondary capture incubated at 65°C for 4 hours and followed by post capture purification and 3-5 cycles of PCR amplification. The resulting pooled, purified libraries were sequenced on the Illumina HiSeq system with 2 × 100 bp paired end reads. The mutation data are available in the cBioPortal for Cancer Genomics at the following URL: https://www.cbioportal.org/study/summary?id=rbl_cfdna_msk_2020.




FIGURE 1 Concept figure showing the application of plasma cfDNA to detect somatic mutations derived from retinoblastoma tumor cells for noninvasive genetic profiling. Reprinted with permission from Memorial Sloan Kettering Cancer Center

2.4 | Data analysis

The detection of somatic mutations from tumor-derived cfDNA can be performed using two approaches: tumor-guided

TABLE 1 Staging at diagnosis and clinical course for this patient cohort

Sample ID	Diagnosis at time of plasma collection		Right eye		Left eye		Anterior Chamber		Extra-ocular extension		Retinal Detachment		Increased intra-ocular pressure		Buphthalmia		Iris neovascularization		Treatment prior to plasma collection		Development of metastatic disease ^a		RBI Clinical Germ-line Testing	
	plasma collection	ICRB (COG)	ICRB (COG)	Optic Nerve involvement	Choroid involvement	Anterior Chamber involvement	Extra-ocular extension	Retinal Detachment	Increased intra-ocular pressure	Buphthalmia	Iris neovascularization	Treatment prior to plasma collection	Development of bilateral disease ^a	Development of metastatic disease ^a	RBI Clinical Germ-line Testing									
P01	Unilateral	E	N/A	No	No	No	No	Yes	No	No	Yes	No	Yes	No	No	No	Yes	No	No	No	Heterozygous <i>RB1</i> c.1072C > T in exon 11	No	No	Heterozygous <i>RB1</i> c.1072C > T in exon 11
P23	Unilateral	N/A	E	No	Yes	No	No	Yes	No	No	Yes	No	No	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	NA
P11	Unilateral	N/A	E	Yes	Yes	No	No	Yes	No	No	Yes	No	No	Yes	No	Yes	Yes	Yes	No	No	No	Yes	Yes	Mosaic del24-26
P03	Unilateral	E	N/A	No	No	No	No	Yes	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	Negative
P21	Unilateral	E	N/A	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Negative
P22	Unilateral	E	N/A	No	No	No	No	Yes	No	No	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	Negative
P26	Unilateral	N/A	E	No	Yes	No	No	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	Negative
P24	Unilateral	N/A	E	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	NA
P16	Unilateral	E	N/A	Yes	No	No	No	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Negative
P19	Unilateral	N/A	E	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	NA

Abbreviations: COG, Children's Oncology Group; ICRB, International classification of retinoblastoma.

^aClinical status of patients in cohort through March 2020.

genotyping with prior knowledge from the matched tumor, or de novo identification of mutations. Genotyping for a known variant will offer more confidence at lower variant allele frequencies (VAF), as the probability of detecting a false positive in cfDNA that is also present in the matched tumor is very low. De novo identification of mutations requires more stringent criteria to allow for confident calls and to eliminate false positive detection.

To evaluate feasibility of detecting *RB1* mutations in plasma cfDNA, we first performed tumor-guided genotyping to search for the *RB1* mutations known from the tumor in the corresponding cfDNA samples using Waltz 2.0.³² To ensure confidence in the calls made by genotyping in the cfDNA samples, each individual patient's *RB1* mutations were also genotyped in the buffy coat samples of the other patients in the cohort. The average variant allele frequency (VAF) for each specific mutation was calculated in the 9 unmatched buffy coats (Table S1). As the mutations are not expected to be found in the unmatched patients, this calculation serves as a rough indicator of the chance of detecting a false positive for the given *RB1* mutation (possibly arising from errors generated during the data generation process). For genotyping known variants, we considered a variant positive if it fulfills all of the following criteria: (a) have at least 3 supporting reads for the alternative allele; (b) the VAF in cfDNA is higher than the VAF in the matching buffy coat from the same patient; and (c) VAF in cfDNA is greater than the average VAF plus 2 standard deviations across the buffy coats of other patients in the cohort. Any calls that had greater than 50% of reads noted as artifact were noted as not detected.

In clinical practice, tumor tissue is not always available, so to further demonstrate the feasibility of detecting *RB1* mutations in plasma without prior molecular profiles from the tumor, we also attempted to identify *RB1* mutations de novo. The cfDNA samples were analyzed with a mutation calling algorithm called VarDict,³³ and a more stringent set of criteria was applied to define mutations as positive, with the intent to decrease the chance of reporting false positive mutations. Identified mutations were then filtered with the following criteria: (a) each mutation in plasma cfDNA must have a VAF of >0.5% with at least 10 mutant allele reads; (b) the VAF of a called mutation must be at least 2 times higher than that the VAF found in its matched buffy coat; (c) the VAF of a called mutation in a given patient must be greater than the average VAF plus 2 standard deviations across the 9 unmatched buffy coats. All the variants that passed these filters were manually reviewed on IGV to remove technical artifacts.

3 | RESULTS

We analyzed plasma cfDNA and tumor tissue from 10 pediatric patients with advanced intra-ocular unilateral retinoblastoma who all underwent eye enucleation (Table 1). Tumor-specific somatic *RB1* mutations were identified by MSK-IMPACT from enucleation samples of all 10 patients. The median age was 30.8 months old at the time of diagnosis (range 0.67-50.2 months). Nine patients did not receive any treatment prior to plasma collection and eye enucleation. One patient received a cycle of systemic




FIGURE 2 *RB1* mutations detected by tumor directed genotyping. Figure 2A: Variant allele frequencies (VAF) of each *RB1* mutation detected in the 10 plasma cfDNA samples obtained. The solid boxes below are plasma cfDNA samples in which the *RB1* mutation was detected by genotyping. Figure 2B: VAFs compared from tumor, cfDNA, and buffy coats of all 10 patients. AF, allele frequency; T, tumor; cf, cfDNA; BC, Buffy Coat




FIGURE 3 De novo identification of somatic *RB1* mutation. Results in both cfDNA and buffy coat are shown. BC, buffy coat; cf, cfDNA

chemotherapy consisting of carboplatin, etoposide, and vincristine prior to plasma collection at an outside institution prior to presentation to this institution. Total plasma cfDNA yields ranged from 5.5 ng to 27.4 ng (mean 17.3 ng). The cfDNA samples were sequenced to an average unique coverage of ~1530x.

Based on the *RB1* mutations reported in tumor sequencing, we first attempted to genotype those mutations in the corresponding cfDNA using the criteria outlined in the Methods. We detected somatic *RB1* mutations in 8 of 10 cfDNA samples, 10 of 13 *RB1* mutations (median VAF 4.9%, range 0.7%–12.6%) (Figure 2). The buffy coat from each patient was concurrently evaluated using the same procedure to filter out germline variants. Of the remaining 2 of 10 cfDNA samples, we observed evidence of tumor guided *RB1* mutations below the detection threshold as defined in the methods in P16 (X702_splice: 5/5666, Q736*: 2/2286 supporting reads), and no evidence of a mutation in P19 (Table S1). Among the cohort, five samples had sufficient leftover cfDNA libraries to repeat the hybridization capture as technical replicates. We

observed concordance between the VAF in both replicates (Figure S1A) with a Pearson correlation of $r^2 = 0.993$.

In practice, tumor tissue is not always available for mutation discovery, requiring de novo identification of *RB1* mutations from plasma cfDNA without prior knowledge. To demonstrate the feasibility of this analysis, we performed de novo calling in the cfDNA samples without referring to information known from the corresponding tumors. Using the criteria outlined in the Methods, we identified *RB1* mutations in 6 of 10 patients in the cohort (7 of 13 mutations), which agreed with the known mutations from matched tumors (Figure 3). Subsequent de novo analysis on the five technical replicates mentioned above revealed concordance between each replicate (Figure S1B). In addition to the expected mutations, based on the same criteria, we also identified two additional *RB1* mutations at 1.56% and 0.99% VAF in cfDNA, respectively, that were not reported in the corresponding tumors (Table S2). We reviewed the tumor mutation data to check if these mutations were present below the detection threshold of MSK-IMPACT, but could not find evidence of them (P22, p.G509E: 0 reads/280 reads; P26, p.P781Q: 0 reads/741 reads). We cannot rule out the possibility that these 2 mutations may be false positive, or could possibly be mosaic mutations derived from a subpopulation of cells from the eye.³⁴ Unfortunately, we did not have sufficient materials to repeat the analysis to verify the possibility of false positive, or another sample from the respective patients to verify the possibility of mosaicism. The current bioinformatics analysis has yet to be improved by interrogating a panel of healthy donor plasma samples to systematically profile the error rate at the level around or below 1% VAF.

In summary, we demonstrated feasibility to detect *RB1* mutations in cfDNA of patients with advanced intraocular disease, 3/10 of whom went on to develop metastatic disease, with an ability to detect *RB1* mutation in 8/10 patients by tumor-guided genotyping, and in 6/10 patients without tumor information by de novo mutation identification.

4 | DISCUSSION

This proof of concept study demonstrates that plasma cfDNA analysis has the potential to detect somatic *RB1* mutations in patients with advanced unilateral retinoblastoma without a detectable germline mutation. We applied two different approaches: genotyping known *RB1* mutations guided by the matched tumor, and de novo analysis without referring to knowledge from the tumor. The former is more sensitive, and the latter is more applicable in the situation where tumor may not be available. In both scenarios we were able to detect somatic *RB1* mutations in plasma of a majority of the patients.

Our results revealed several interesting observations. It was observed that plasma analysis can potentially detect somatic *RBI* mutations that are present as the second hit in addition to the germline *RBI* mutation in a given patient. For example, patient P01 was reported to carry an *RBI* germline mutation according to a separate clinical test. Interestingly, tumor and cfDNA analysis identified a different *RBI* mutation, present at VAF of 1.37% in cfDNA and not detectable in the matched buffy coat, suggesting that it is likely somatic, as germline variants detected in cfDNA are typically at a VAF around 50%. This patient went on to develop bilateral disease. This somatic mutation identified in the cfDNA is likely the second hit to the *RBI* gene that are associated with the development of bilateral retinoblastoma.

The VAFs of *RBI* mutations in cfDNA tend to be higher in patients that went on to develop metastatic disease. Of the three patients that developed metastasis, two patients (P23 and P11) had the highest *RBI* mutation VAFs from cfDNA in this study (12.6% and 8.1% respectively). P23 had metastatic recurrence of disease 3 months after eye enucleation with right orbit recurrence and bone marrow disease, whereas other patients in this cohort who went on to develop metastatic disease did so at an average of 10 months from initial diagnosis and enucleation (P11, P16). It is likely the higher VAF noted in P23's sample is representing a higher disease burden²⁷ or microscopic metastatic disease. In the other two patients (P11 and P16) who eventually developed metastasis, the cfDNA sample from P11 showed the second highest VAF at 8.1%; however, both mutations in P16 were only identified at subthreshold levels. Although higher VAFs may correspond with a higher risk of metastatic disease, a larger sample cohort would be required to truly determine the correlation. These findings also suggest that longitudinally tracking *RBI* mutations in cfDNA may allow for early detection of disease recurrence. Indeed, feasibility has been demonstrated in adult solid tumors.^{35,36} Further work needs to be done to understand the implication of changes around low-level VAF (eg <1%), as variations may be introduced by sampling error and should not be mistaken as tumor response. Nonetheless, our results agree with the positive correlation between disease metastasis and tumor cfDNA levels reported in other solid tumors.

The level of tumor-derived cfDNA in plasma likely drops after systemic chemotherapy, thus hindering the ability to detect the *RBI* mutations in cfDNA. For example, in the 7 patients with unilateral retinoblastoma, we detected the *RBI* mutations from cfDNA in 6 of 7 samples, except sample P19 despite a unique coverage of 1596x. The mutation may be present in the plasma at levels below the theoretical detection limit of 3 in 1596 (0.18%). P19 is the only patient in the cohort that received 1 cycle of systemic chemotherapy prior to enucleation (due to the family's preference for eye salvage). It is possible that the amount of circulating tumor-derived cfDNA had already decreased at the time of blood draw as a

result of this therapy.³⁷ Therefore, the timing of blood draw is critical if the intent is to determine somatic *RBI* status for diagnostic purposes.

To apply this tool in the clinic for definitive identification of somatic *RBI* mutations, it is critical to validate the analytical performance of the assay to ensure the accuracy, reproducibility, limits of detection, and false positive rate are fully characterized. When performing de novo mutation identification in cfDNA, it will be important to further evaluate the false positive rate by analyzing a large panel of healthy donor's plasma cfDNA. The sensitivity and accuracy of detecting low VAF *RBI* mutations could theoretically be improved by analyzing the samples in replicates, or by incorporating unique molecular identifiers with deeper sequencing to reduce the background errors introduced during the process.^{38,39} High confident mutation discovery below 1% VAF will also be important for identifying mosaic *RBI* mutations derived from sub-population of the eyes that are absent in the tumor. The identification of low level mosaicism would be an interesting to explore in future study by collecting multiple sample types from the same patient across time to observe if the mutation levels persist or change with treatment.

It is worth noting that the patients in this study had advanced intraocular disease with a relatively higher rate of metastasis than the general retinoblastoma population. This is partly because most of the retinoblastoma patients at MSKCC received treatment that preserved their vision, and in this study we deliberately included patients who have tumor samples available as a result of eye enucleation such that we can compare the *RBI* mutation status in plasma with tumor. The stage of disease seen in these patients, although advanced, was still limited to a unilateral eye at the time of diagnosis. As it is known that advanced tumors shed more tumor derived cfDNA^{27,37}; future studies are needed to determine the feasibility to detect somatic *RBI* mutations from cfDNA in patients with earlier stages of retinoblastoma. Besides *RBI* mutations, a small proportion of patients (1%) with retinoblastoma may have *MYCN* amplifications driving their disease, not an *RBI* loss of function mutation.^{10,40,41} Although the current study focuses on *RBI* mutation analysis, previous work has shown that cfDNA can also reveal tumor-derived somatic copy number alterations including changes in *MYCN*.⁴²⁻⁴⁴ Incorporating mutational and copy number analysis can potentially expand the scope of patient population and the sensitivity of detecting tumor-derived cfDNA at diagnosis and in the relapse setting. Blood samples are safe to obtain and could potentially eliminate the risks of repeated exams under anesthesia in such young patients. Germline mutation analysis could also be completed using the same methodology by looking for the *RBI* mutation in both the buffy coat DNA and plasma cfDNA from a single blood sample

which would be useful for patients with both unilateral and bilateral disease presentation.

In conclusion, this study demonstrates the feasibility of using plasma cfDNA to obtain a molecular profile of retinoblastoma by determining the key mutations in the *RB1* gene. As treatment of retinoblastoma continues to improve ocular survival, fewer tissue samples will be available to determine the tumor's mutational profile, and an alternative method to determine the *RB1* mutation status will be required. Identification of an *RB1* mutation by cfDNA and demonstration of its absence in the buffy coat can potentially determine whether or not the patient has a somatic *RB1* mutation. Although examination under anesthesia cannot be fully eliminated, *RB1* gene monitoring via plasma cfDNA has the potential to provide data to supplement the clinical management in these young patients. This will minimize their exposure to sedation and the risks associated with each examination. The results from this proof of concept study should be further evaluated in large cohorts that involve all stages of retinoblastoma patients, using a fully validated assay to further improve the accuracy of detecting low-level *RB1* mutation in plasma DNA. We envision that plasma cfDNA analysis will play an important role in both diagnosis and monitoring of response to treatment in patients with retinoblastoma.

DATA AVAILABILITY STATEMENTS

The mutation data are available in the cBioPortal for Cancer Genomics at the following URL: https://www.cbioportal.org/study/summary?id=rbl_cfdna_msk_2020.

ACKNOWLEDGMENTS

In addition to our funding support, we thank the families and children with retinoblastoma who contributed to this research. We acknowledge the contribution by the cfDNA extraction laboratory at the Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center. We also thank Erika Gedvilaite for her technical support throughout the project, and Joseph Olechnowicz and Michelle Lamendola-Essel for their editorial assistance.

CONFLICT OF INTEREST

PK, JY, CMS, DS, XJ, JE, KH, AV, JHF, NS, and DHA have nothing to disclose. MFB, DWYT, JP, MH, and FM are co-inventors on a provisional patent application for systems and methods for detecting cancer via cfDNA screening (PCT/US2019/027487). DT and FM are co-inventors on a provisional patent application for systems and methods for distinguishing pathological mutations from clonal hematopoietic mutations in plasma cell-free DNA by fragment size analysis. MFB has received consulting fees from Roche and grant support from Illumina and Grail. DT has received research support from ThermoFisher Scientific, EPIC Sciences,

speaking honoraria and travel support from Nanodigmbio, Cowen, BoA Merrill Lynch. IJD reports non-financial support from Apexigen, personal fees from Bayer, grants from Bristol-Myers Squibb, personal fees from Celgene, grants from Genentech, grants from Novartis, outside the submitted work.

AUTHOR CONTRIBUTIONS

PK, NS, IJD, and DWYT contributed to conceptualization. JE, JHF, DHA, and IJD contributed to patient recruitment and sample collection. PK, FM, XJ, KH, AV, and MFB contributed to collection and assembly of data. Data Curation and Formal Analysis: PK, JY, FM, CMS, DS, MH, JP, MFB, IJD, and DWYT contributed to data curation and formal analysis. PK wrote the first draft of the paper and all authors approved the final version.

ORCID

Prachi Kothari  <https://orcid.org/0000-0002-3137-844X>
 Francesco Marass  <https://orcid.org/0000-0002-8993-7320>
 Julie L. Yang  <https://orcid.org/0000-0003-4747-6391>
 Caitlin M. Stewart  <https://orcid.org/0000-0002-5070-4810>
 Ira J. Dunkel  <https://orcid.org/0000-0001-8091-6067>
 Dana W.Y. Tsui  <https://orcid.org/0000-0002-0595-6664>

REFERENCES

1. Ries LAGSM, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). *Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995*. Bethesda, MD: National Cancer Institute; 1999.
2. Dimaras H, Kimani K, Dimba EAO, et al. Retinoblastoma. *Lancet (London, England)*. 2012;379(9824):1436-1446.
3. Broadus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975–2004. *The British journal of ophthalmology*. 2009;93(1):21-23.
4. Brichard B, Heusterspreute M, De Potter P, et al. Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation. *Eur J cancer (Oxford, England : 1990)*. 2006;42(1):65-72.
5. Mendoza PR, Grossniklaus HE. The Biology of Retinoblastoma. *Progress in molecular biology and translational science*. 2015;134:503-516.
6. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci USA*. 1971;68(4):820-823.
7. Price EA, Price K, Kolkiewicz K, et al. Spectrum of RB1 mutations identified in 403 retinoblastoma patients. *J Med Genet*. 2014;51(3):208-214.
8. Pizzo P, Poplack DG. *Principles and Practice of Pediatric Oncology* (6th ed.). Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
9. Theriault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: a review. *Clin Exp Ophthalmol*. 2014;42(1):33-52.
10. Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. *Lancet Oncol*. 2013;14(4):327-334.

11. Abramson DH, Fabius AWM, Issa R, et al. Advanced unilateral retinoblastoma: the impact of ophthalmic artery chemosurgery on enucleation rate and patient survival at MSKCC. *PLoS ONE*. 2015;10(12):e0145436.
12. Abramson DH. Retinoblastoma: saving life with vision. *Annu Rev Med*. 2014;65(1):171-184.
13. Abramson DH, Francis JH, Gobin YP. What's new in intra-arterial chemotherapy for retinoblastoma? *Int Ophthalmol Clin*. 2019;59(2):87-94.
14. Berry JL, Xu L, Kooi I, et al. Genomic cfDNA Analysis of Aqueous Humor in Retinoblastoma Predicts Eye Salvage: The Surrogate Tumor Biopsy for Retinoblastoma. *Mol Cancer Res*. 2018;16(11):1701-1712.
15. Ortiz MV, Dunkel IJ. Retinoblastoma. *J Child Neurol*. 2016;31(2):227-236.
16. Dommering CJ, Mol BM, Moll AC, et al. RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients. *J Med Genet*. 2014;51(6):366-374.
17. Harbour JW. Overview of RB gene mutations in patients with retinoblastoma Implications for clinical genetic screening. *Ophthalmology*. 1998;105(8):1442-1447.
18. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. *J Natl Cancer Inst*. 1993;85(14):1121-1128.
19. Kleinerman RA, Yu C-L, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. *J Clin Oncol*. 2012;30(9):950-957.
20. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. *J Clin Oncol*. 2005;23(10):2272-2279.
21. Berry JL, Xu L, Murphree AL, et al. Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. *JAMA ophthalmology* 2017;135(11):1221.
22. Laurent VE, Sampor C, Solernou V, et al. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. *Eur J Cancer (Oxford, England : 1990)*. 2013;49(13):2892-2899.
23. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol*. 2014;32(6):579-586.
24. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *New Eng J Med*. 2013;368(13):1199-1209.
25. Murtaza M, Dawson S-J, Tsui DWY, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature*. 2013;497(7447):108-112.
26. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. *Oncology*. 1989;46(5):318-322.
27. Bettgowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. 2014;6(224):224ra224.
28. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature*. 2017;545(7655):446-451.
29. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. *J Mol Diagn*. 2015;17(3):251-264.
30. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med*. 2017;23(6):703-713.
31. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012;491(7422):56-65.
32. Waltz PJ. A fast, efficient bam pileup and application modules based on it, like coverage metrics, genotyping, signature finding etc. Version 2.0. <https://github.com/juberpatel/Waltz>
33. Lai Z, Markovets A, Ahdesmaki M, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. *Nucleic Acids Res*. 2016;44(11):e108.
34. Tomar S, Sethi R, Sundar G, Quah TC, Quah BL, Lai PS. Mutation spectrum of RB1 mutations in retinoblastoma cases from Singapore with implications for genetic management and counselling. *PLoS ONE*. 2017;12(6):e0178776.
35. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. *Sci Transl Med*. 2016;8(346):346ra392.
36. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. *Sci Transl Med*. 2015;7(302):302ra133.
37. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. *Can Res*. 1977;37(3):646-650.
38. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. *Proc Natl Acad Sci*. 2011;108(23):9530-9535.
39. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. *Nat Biotechnol*. 2016;34(5):547-555.
40. Bowles E, Corson TW, Bayani J, et al. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. *Genes Chromosom Cancer*. 2007;46(2):118-129.
41. Felsher DW. Role of MYCN in retinoblastoma. *Lancet Oncol*. 2013;14(4):270-271.
42. Chicard M, Boyault S, Colmet Daage L, et al. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. *Clin Cancer Res*. 2016;22(22):5564-5573.
43. Kothari P, Yang J, Berger MF, Shukla NN, Modak S, Tsui D. Plasma cell-free DNA for noninvasive molecular profiling in high-risk stage 4 neuroblastoma. *J Clin Oncol*. 2018;36(15_suppl):10554-10554.
44. Heitzer E, Ulz P, Belic J, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. *Genome Med*. 2013;5(4):30.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Kothari P, Marass F, Yang J, et al. Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience. *Cancer Med*. 2020;9:6093–6101. <https://doi.org/10.1002/cam4.3144>